KR101698362B1 - Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질 - Google Patents

Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질 Download PDF

Info

Publication number
KR101698362B1
KR101698362B1 KR1020117009012A KR20117009012A KR101698362B1 KR 101698362 B1 KR101698362 B1 KR 101698362B1 KR 1020117009012 A KR1020117009012 A KR 1020117009012A KR 20117009012 A KR20117009012 A KR 20117009012A KR 101698362 B1 KR101698362 B1 KR 101698362B1
Authority
KR
South Korea
Prior art keywords
amino acid
leu
ala
acid residue
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117009012A
Other languages
English (en)
Korean (ko)
Other versions
KR20110082528A (ko
Inventor
한스 카스파르 빈즈
패트릭 포러
마이클 토비아스 스텀프
Original Assignee
몰리큘라 파트너스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 몰리큘라 파트너스 아게 filed Critical 몰리큘라 파트너스 아게
Publication of KR20110082528A publication Critical patent/KR20110082528A/ko
Application granted granted Critical
Publication of KR101698362B1 publication Critical patent/KR101698362B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117009012A 2008-11-03 2009-11-03 Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질 Active KR101698362B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168166 2008-11-03
EP08168166.0 2008-11-03
PCT/EP2009/064483 WO2010060748A1 (en) 2008-11-03 2009-11-03 Binding proteins inhibiting the vegf-a receptor interaction

Publications (2)

Publication Number Publication Date
KR20110082528A KR20110082528A (ko) 2011-07-19
KR101698362B1 true KR101698362B1 (ko) 2017-01-20

Family

ID=40149742

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117009012A Active KR101698362B1 (ko) 2008-11-03 2009-11-03 Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질

Country Status (15)

Country Link
US (2) US8901076B2 (enExample)
EP (2) EP2358746B1 (enExample)
JP (2) JP5954990B2 (enExample)
KR (1) KR101698362B1 (enExample)
CN (2) CN102272148A (enExample)
AU (1) AU2009319204B2 (enExample)
BR (1) BRPI0921469B1 (enExample)
CA (1) CA2742241C (enExample)
DK (1) DK2358746T3 (enExample)
ES (1) ES2836948T3 (enExample)
IL (1) IL212589A (enExample)
MX (2) MX2011004649A (enExample)
NZ (1) NZ592591A (enExample)
RU (2) RU2650765C1 (enExample)
WO (1) WO2010060748A1 (enExample)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007062676A1 (en) 2005-12-01 2007-06-07 B.R.A.H.M.S. Aktiengesellschaft Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
AU2014243418B2 (en) * 2010-04-30 2016-09-22 Molecular Partners Ag Modified binding proteins inhibiting the VEGF-A receptor interaction
TWI510246B (zh) * 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
KR101782790B1 (ko) * 2010-11-26 2017-09-28 몰리큘라 파트너스 아게 혈청 알부민에 결합하는 설계된 반복 단백질
KR20140039203A (ko) 2011-04-29 2014-04-01 얀센 바이오테크 인코포레이티드 Il4/il13 결합 반복 단백질 및 용도
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
EP2780370B1 (en) 2011-11-16 2019-09-25 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
SG10201802054TA (en) 2011-11-16 2018-05-30 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
SG11201402362VA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
PT2594588E (pt) 2011-11-16 2014-08-28 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou andaime proteico não ig anti-adm para utilização em terapia
HUE032648T2 (en) 2011-11-16 2017-10-30 Sphingotec Gmbh Adrenomedullin assays and procedures for determining the concentration of mature adrenomedullin
PT3553084T (pt) 2011-11-16 2023-02-17 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou esqueleto não-ig anti-adm para prevenção ou redução de disfunção de órgãos ou insuficiência de órgãos num paciente possuindo uma doença crónica ou aguda ou condição aguda
CN103308670B (zh) 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
CN103308673B (zh) 2012-03-08 2017-05-31 思芬构技术有限公司 用于预测雌性对象中发生心血管事件的风险的方法
CN103308689B (zh) 2012-03-08 2017-04-12 思芬构技术有限公司 用于预测雌性对象中患上癌症的风险或诊断癌症的方法
US10568934B2 (en) * 2012-05-07 2020-02-25 Allergan, Inc. Method of treating AMD in patients refractory to anti-VEGF therapy
LT3679922T (lt) 2012-06-01 2021-10-25 Novartis Ag Švirkštas
KR20150023957A (ko) * 2012-06-28 2015-03-05 몰리큘라 파트너스 아게 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
AU2013100070B4 (en) * 2012-07-03 2013-04-04 Novartis Ag Use of device
AU2012101677B4 (en) 2012-07-03 2012-12-20 Novartis Ag Device
US20150297675A1 (en) * 2012-08-28 2015-10-22 Aaron Osborne Use of a vegf antagonist in treating ocular vascular proliferative diseases
DK2904403T3 (en) 2012-10-02 2018-07-16 Sphingotec Gmbh PROCEDURE FOR DIAGNOSTICATION OR MONITORING OF Kidney Function or Diagnosis of Kidney Function
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US20150346222A1 (en) 2013-01-08 2015-12-03 Sphingotec Gmbh Fasting levels of growth hormone as a predictive marker of cardiovascular risk
EP3444278A1 (en) * 2013-02-26 2019-02-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
WO2014151725A1 (en) * 2013-03-14 2014-09-25 Allergan, Inc. Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process
US10598674B2 (en) 2013-03-20 2020-03-24 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
JP2016522249A (ja) 2013-06-20 2016-07-28 ノバルティス アーゲー 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
EP3010542A1 (en) 2013-06-20 2016-04-27 Novartis AG Treatment of polypoidal choroidal vasculopathy
EP3010526A1 (en) 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating macular edema
US20160168240A1 (en) * 2013-07-11 2016-06-16 Sergey AKSENOV Use of vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
RU2676303C2 (ru) * 2013-07-11 2018-12-27 Новартис Аг Использование антагониста vegf для лечения ретролентальной фиброплазии
EP3019243A4 (en) 2013-07-12 2017-03-15 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
PT3065761T (pt) * 2013-11-05 2020-02-21 Allergan Inc Método de tratamento de condições oculares com um darpin anti-vegf
EP3492495A1 (en) 2014-05-12 2019-06-05 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
EP3002589A1 (en) 2014-10-01 2016-04-06 sphingotec GmbH A method for stratifying a female subject for hormone replacement therapy
SG11201707606RA (en) * 2015-04-02 2017-10-30 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
JP6841765B2 (ja) 2015-04-24 2021-03-10 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 慢性腎疾患の発症のリスクを予測するための方法
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
CA3005132A1 (en) 2015-11-18 2017-05-26 Sio2 Medical Products, Inc. Coated syringe for ophthalmic formulations containing a vegf antagonist
WO2017085253A1 (en) 2015-11-18 2017-05-26 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
RU2734958C2 (ru) 2015-11-18 2020-10-26 Формикон Аг Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
CN115951066A (zh) 2016-02-29 2023-04-11 麦恩泰科特有限公司 可用于治疗湿性年龄相关性黄斑变性的预测性标志物
EP3854817A1 (en) 2016-04-21 2021-07-28 4TEEN4 Pharmaceuticals GmbH Methods for determining dpp3 and therapeutic methods
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
EP3482208B1 (en) 2016-07-08 2023-04-12 SphingoTec GmbH Adrenomedullin for assessing congestion in a subject with acute heart failure
AU2017299581B2 (en) 2016-07-20 2024-05-23 EyePoint Pharmaceuticals, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-β)
NZ751689A (en) 2016-09-22 2021-07-30 Molecular Partners Ag Recombinant binding proteins and their use
EP3309550A1 (en) 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
MX2019007107A (es) 2016-12-16 2019-10-21 Adrenomed Ag Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo.
EP3339324A1 (en) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
CA3063995A1 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
CA3065415A1 (en) 2017-05-30 2018-12-06 Sphingotec Gmbh A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
BR112020003377A2 (pt) 2017-08-18 2020-08-25 Cambridge Enterprise Limited proteínas de ligação modulares
CA3076691A1 (en) 2017-09-25 2019-03-28 Adrenomed Ag Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
EP3698134A1 (en) 2017-10-18 2020-08-26 AdrenoMed AG Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
AU2018356370A1 (en) 2017-10-24 2020-04-09 Sphingotec Gmbh Selenoprotein P for prediction of a first cardiovascular event
CN111542548B (zh) 2017-10-25 2024-07-30 4Teen4制药有限公司 针对并结合于特异性dpp3表位的dpp3结合剂及其在预防或治疗与氧化应激相关的疾病/急性病状中的用途
AU2019219071A1 (en) 2018-02-08 2020-07-30 Sphingotec Gmbh Adrenomedullin (ADM) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
JP7695187B2 (ja) 2018-09-24 2025-06-18 アイポイント ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
AU2019408553A1 (en) 2018-12-20 2021-06-17 Sphingotec Gmbh Selenoprotein P in heart failure
US20220211798A1 (en) 2018-12-21 2022-07-07 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
US20200385488A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins
EP4014049A1 (en) 2019-08-15 2022-06-22 sphingotec GmbH A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients
CN114556100A (zh) 2019-08-30 2022-05-27 4Teen4制药有限公司 用于治疗休克的疗法指引和/或疗法监测
IL293698A (en) 2019-12-11 2022-08-01 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins, their production and use
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
WO2021170880A2 (en) 2020-02-27 2021-09-02 Adrenomed Ag Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
BR112022015215A2 (pt) 2020-02-27 2022-10-11 4TEEN4 Pharmaceuticals GmbH Dpp3 para orientação, monitoramento e estratificação de terapia de anticorpos nt-adm em pacientes com choque
JP2023515042A (ja) 2020-02-27 2023-04-12 アドレノメト アクチェンゲゼルシャフト ショックの治療若しくは予防において使用するための抗アドレノメデュリン（ＡＤＭ）抗体若しくは抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
US20210285949A1 (en) 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
US20230213519A1 (en) 2020-03-16 2023-07-06 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
AU2021267411A1 (en) 2020-05-06 2022-12-08 Molecular Partners Ag Novel ankyrin repeat binding proteins and their uses
JP2023528204A (ja) 2020-05-14 2023-07-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
EP4023218A1 (en) 2020-12-02 2022-07-06 S-Form Pharma Combination therapy for patients having acute and/or persistent dyspnea
US20240108746A1 (en) 2020-12-16 2024-04-04 Molecular Partners Ag Novel slow-release prodrugs
EP4305063A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Protease cleavable prodrugs
WO2022190018A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
JP2024508969A (ja) 2021-03-09 2024-02-28 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ
JP2024509904A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ
US12472148B2 (en) 2021-04-26 2025-11-18 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2022263648A1 (en) 2021-06-18 2022-12-22 Sphingotec Gmbh A method for predicting sepsis and septic shock
WO2023275099A1 (en) 2021-06-29 2023-01-05 Berysol Gmbh Composite biomarker for the identification of selenium deficiency in a bodily fluid
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
JP2025509304A (ja) 2022-03-15 2025-04-11 アドレノメト アクチェンゲゼルシャフト 抗アドレノメデュリン（ａｄｍ）抗体又は抗ａｄｍ抗体フラグメントの安定な水性製剤
EP4562430A1 (en) 2022-07-29 2025-06-04 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock
JP2025525059A (ja) 2022-07-29 2025-08-01 アドレノメト アクチェンゲゼルシャフト ショックの治療又は予防に使用するための抗アドレノメデュリン（ＡＤＭ）抗体若しくは抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
CA3262553A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag REHEARSAL AREAS DESIGNED WITH MODIFIED CHARGES AND THEIR USE
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024059686A2 (en) * 2022-09-15 2024-03-21 The Regents Of The University Of California Darpin backbones and rigidified electron microscopy imaging scaffolds
CN120359042A (zh) 2022-12-15 2025-07-22 4Teen4制药有限公司 改善危重病患者肺功能的dpp3抑制剂
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
WO2024194276A1 (en) 2023-03-17 2024-09-26 Pam Theragnostics Gmbh Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose
WO2024200862A1 (en) 2023-03-29 2024-10-03 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
WO2025068313A1 (en) 2023-09-25 2025-04-03 Sphingotec Gmbh A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025229075A1 (en) 2024-05-03 2025-11-06 Sphingotec Gmbh A method for the specific determination of proenkephalin fragment 119-159
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056764A2 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
ES2361267T3 (es) 1997-04-07 2011-06-15 Genentech Inc. Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
EP0975748B1 (en) 1997-04-23 2006-03-29 Universität Zürich Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
NZ511699A (en) 1998-12-02 2003-02-28 Phylos Inc DNA-protein fusions and uses thereof
BRPI0011407B8 (pt) 1999-06-08 2021-05-25 Regeneron Pharma molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
RU2299208C2 (ru) * 2001-05-08 2007-05-20 Шеринг Акциенгезельшафт Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
NZ591733A (en) * 2004-11-12 2012-10-26 Bayer Schering Pharma Ag Recombinant newcastle disease virus comprising a transgene encoding a fusion protein comprising a binding domain and a heterologous domain comprising an enzyme
ES2633574T3 (es) * 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
DK1902131T3 (da) 2005-07-08 2010-03-01 Univ Zuerich Fag-display under anvendelse af cotranslational translokation af fusionspolypeptider
CA2670471A1 (en) * 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
AU2008210521A1 (en) * 2007-02-01 2008-08-07 Genentech, Inc. Combination therapy with angiogenesis inhibitors
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056764A2 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY. 2004, vol. 5, no. 2, pp. 183-189.
DRUG DISCOVERY TODAY. 2008.07.11., vol. 13, no. 15-16, pp. 695-701.
THE FASEB JOURNAL. 2002, vol. 16, no. 2, pp. 219-221.*

Also Published As

Publication number Publication date
BRPI0921469A2 (pt) 2016-01-12
DK2358746T3 (da) 2020-12-21
MX359570B (es) 2018-10-01
JP5954990B2 (ja) 2016-07-20
EP3785735A1 (en) 2021-03-03
MX2011004649A (es) 2011-05-30
JP2015133978A (ja) 2015-07-27
EP2358746B1 (en) 2020-09-16
IL212589A0 (en) 2011-07-31
EP2358746A1 (en) 2011-08-24
IL212589A (en) 2017-01-31
CA2742241C (en) 2019-12-10
NZ592591A (en) 2012-04-27
JP2012507271A (ja) 2012-03-29
US20150344539A1 (en) 2015-12-03
CN107011425A (zh) 2017-08-04
JP6329503B2 (ja) 2018-05-23
RU2011122201A (ru) 2012-12-10
ES2836948T3 (es) 2021-06-28
CA2742241A1 (en) 2010-06-03
AU2009319204B2 (en) 2014-11-13
RU2650765C1 (ru) 2018-04-17
US20110207668A1 (en) 2011-08-25
RU2550258C2 (ru) 2015-05-10
US8901076B2 (en) 2014-12-02
BRPI0921469B1 (pt) 2022-01-18
CN102272148A (zh) 2011-12-07
WO2010060748A1 (en) 2010-06-03
KR20110082528A (ko) 2011-07-19
CN107011425B (zh) 2021-01-01
AU2009319204A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
KR101698362B1 (ko) Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질
US10646542B2 (en) Modified binding proteins inhibiting the VEGF-A receptor interaction
HK1238258B (zh) 抑制vegf-a受体相互作用的结合蛋白
HK1179876B (en) Modified binding proteins inhibiting the vegf-a receptor interaction
AU2014243418A1 (en) Modified binding proteins inhibiting the VEGF-A receptor interaction
HK1179876A (en) Modified binding proteins inhibiting the vegf-a receptor interaction

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110420

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140328

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151210

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20161027

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170116

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170117

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20200103

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20200103

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210107

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230105

Start annual number: 7

End annual number: 7